Tristel PLC
LSE:TSTL
Tristel PLC
Tristel Plc engages in the design, development, manufacture, and sale of infection control, contamination control and hygiene products. The company is headquartered in Snailwell, Cambridgeshire and currently employs 189 full-time employees. The company went IPO on 2005-06-01. The Company’s technology is a chlorine dioxide formulation used by hospitals for the high-level disinfection of medical devices and the sporicidal disinfection of environmental surfaces. The Company’s segments include Hospital medical device decontamination and Hospital environmental surface disinfection. The firm manufactures and sells medical device decontamination products that are used primarily for infection control in hospitals. The firm also manufactures and sells hospital environmental surface disinfection products. The Tristel brand offers airway management, cardiology, ear, nose and throat, ophthalmology, endoscopy, phlebotomy, surfaces, ultrasound, urology, and women's health. The Crystel brand offers pharmaceutical, cosmetic and toiletry (PCT), cleanroom disinfectants and laboratory disinfectants. The company markets its products under the Tristel, Anistel, and Crystel brands.
Tristel Plc engages in the design, development, manufacture, and sale of infection control, contamination control and hygiene products. The company is headquartered in Snailwell, Cambridgeshire and currently employs 189 full-time employees. The company went IPO on 2005-06-01. The Company’s technology is a chlorine dioxide formulation used by hospitals for the high-level disinfection of medical devices and the sporicidal disinfection of environmental surfaces. The Company’s segments include Hospital medical device decontamination and Hospital environmental surface disinfection. The firm manufactures and sells medical device decontamination products that are used primarily for infection control in hospitals. The firm also manufactures and sells hospital environmental surface disinfection products. The Tristel brand offers airway management, cardiology, ear, nose and throat, ophthalmology, endoscopy, phlebotomy, surfaces, ultrasound, urology, and women's health. The Crystel brand offers pharmaceutical, cosmetic and toiletry (PCT), cleanroom disinfectants and laboratory disinfectants. The company markets its products under the Tristel, Anistel, and Crystel brands.
Revenue: Group revenue rose 14% to GBP 25.6 million in H1, driven by both UK growth and stronger US traction.
Profitability: Adjusted profit before tax was GBP 5.5 million (up 11%); adjusted EBITDA margin was 29% (above the 25% commitment).
US momentum: Tristel ULT in‑market sales are approaching USD 1 million (320,000 procedures in H1) with royalties of GBP 116,000; management expects to exceed USD 2 million in in‑market sales by year‑end.
New product uptake: Tristel OPH has generated USD 88,000 revenue in H1 and already secured 43 active users; VISICLEAN has begun commercial roll‑out with positive customer reaction.
Cash & balance sheet: Cash and deposits of GBP 13.3 million, debt free; GBP 6.7 million cash generated in H1 and an interim dividend of 5.68p to be paid in April.
Investment push: Company is increasing commercial hiring (adding 13 heads this year), expanding clinical leadership and investing in digital/CRM and SaaS development to scale growth.
